Rankings Pharma & medtech Sernova
Sernova
35
15070100
A view of the same findings, not a new score. How it works
The model found several serious problems. That does not mean the stock will fall.
Biggest deductions
- Margin−12
- Going concern and liquidity−12
- Valuation−10
Strengths
- Clinical validation+3
- Insider buying+2
Speculative profile
A penny stock under DKK 3. The asymmetry rating is separate from the Bjarvik score and is not a recommendation.
- Asymmetry (1–10)
- 3
- Price
- 0.49 DKK
- Market value
- DKK 184m
- Cash runway
- 0 months
- Cash / debt
- 0.1 / 2.6m CAD
- Dilution, 12 months
- +7%
Bull case
The merger closes, BetaNova gets a Nasdaq listing, and SR-02 shows insulin production without donor cells in mid-2027 – combined with Cell Pouch's 8/12 insulin-independent. Stem cell islet cells are one of the hottest diabetes areas (Vertex has shown the way), so a combined company at 300–500 m USD is possible; Sernova shareholders' roughly 50% (before notes) could then be 3–8x today's roughly 29 m USD.
Bear case
The merger collapses (shareholders, the court or lack of financing), and Sernova is left with 63,000 C$ in cash and −11.7 m in working capital – that means an emergency issue at a few cents or insolvency. If the merger closes, Sernova shareholders are diluted by the notes and new issues before Nasdaq, and SR-02 could disappoint.
Catalysts
- Nov 2026Shareholder meeting and closing of the merger of Seraxis into BetaNova Biotherapeutics (requires 2/3 majority, court and TSX approval); Sernova shareholders get about 50%binary globenewswire.com
- Q1 2027First patients dosed in the FDA-approved phase 1/2 with SR-02 (stem cell-based islet cells, NCT07581197) and planned Nasdaq listing of BetaNovagradual globenewswire.com
- Mid-2027First data from the SR-02 trialbinary streetwisereports.com
Risk of going to zerohigh – cash is empty and working capital −C$11.7m; survival depends entirely on the merger and the insiders' notes being completed.
Next financingCash of C$63,000 and working capital of −C$11.7m at 31/7-2026 – in reality no runway (operating cash flow approx. −C$1.1m per quarter, held down by deferred payments). The company depends on US$10m (approx. C$13.9m) in convertible notes from insiders, which follow the merger with Seraxis (closing expected November 2026), and BetaNova must then raise more for the SR-02 trial and a Nasdaq listing in Q1 2027.
Warrants & convertiblesFrom March 2026: about 10.7 m warrants at 0.25 C$ (36 months), 10 m warrants at 0.25 C$ to the bondholder, 26.7 m warrants at 0.20 C$ (36 months, insider); convertible bond 1.5 m C$ at 0.15 C$ (10 m shares, 10% interest). September 2026: US$10 m convertible notes to insiders, converting into BetaNova shares at the merger (price not disclosed). Older warrants and options not tallied.
Insiders, last 12 monthsMarch 2026: an insider/director subscribed for 26.67m units for C$4.0m at C$0.15 (approved at the general meeting on 8/4-2026) and provided a convertible bond of C$1.5m at C$0.15. September 2026: insiders in Sernova and Seraxis are behind US$10m in convertible notes. Sales not found (not systematically checked).
Largest ownersNot examined in detail. Stockanalysis: insiders c. 13.5%, institutions c. 0%.
Circio check(1) Small market cap: yes – approx. DKK 184m. (2) Hot theme: yes – cell therapy/stem-cell-derived islet cells against type 1 diabetes. (3) Upcoming milestones: yes – merger in November, SR-02 dosing Q1 2027 and data mid-2027. (4) Major partner: no – no big pharma partner; funding comes from insiders. (5) Funding for 2+ years: no – cash is empty, and US$10m only covers the first part of SR-02. (6) Price near the bottom: yes – −92% from 2021 and below the March issue price.
Why this asymmetryThere is real clinical validation and a hot theme, and a successful merger with SR-02 data could give a sharp rise. But shareholders share the upside 50/50 with Seraxis, are diluted further by notes and issues, and if the merger fails, the company is effectively insolvent – binary risk with a limited share of the gain.
How the score is built
From 100 to 35, step by step: points off for the business, the price and the cracks, back for documented strengths, then three data adjustments.
Start
Score
Hover or select a step to see what drove it. Steps with findings open them below.
Key numbers
As of 2 Nov 2026. Analyst targets tend to be optimistic; read upside as a hint, not a forecast.
- Price
- 0.10 CAD
- Median analyst target
- –
- Upside to median
- –
- Analysts
- none
- Target range
- –
- 52-week change
- −33%
- P/E (trailing)
- n/a
- Forward P/E
- n/a
- PEG
- n/a
Findings
Every deduction and every plus, with its source. Open a step to read them.
Business
Is the company getting stronger, not just bigger? · 3 findings−25 of −30
- −12MarginNo revenue; operating loss −C$8.9m TTM and losses every year (−C$40.5m in 2023, −31.7m in 2024, −15.0m in 2025). The loss has only fallen because the money ran out (8 employees).
- −8Moat and competitionCell Pouch with donor cells requires immunosuppression and has limited donor supply; competitors such as Vertex's stem-cell islet cells are far ahead, and Sernova's own stem-cell path (SR-02) comes via merger partner Seraxis, not its own technology.
- −5Capital allocationCash has fallen from C$49.8m in 2022 to C$0.06m in just under four years without reaching phase 3; the company ends up as a minority party (approx. 50%) in a merger in which Seraxis is the surviving company, and the confirmatory Cohort C has been awaiting financing.
Price
Today's multiples against the company's own history and its peers. · 1 finding−10 of −35
- −10ValuationNo revenue or earnings to measure against; negative equity (−C$11.8m, P/B −3.4) and EV of C$54m above market cap because of debt and debt-like items. The value is a pure option on the merger and a stem cell trial, where the Sernova shareholders share the upside 50/50 and are diluted by convertible notes at an unknown price.
Cracks
Cash flow, customers, debt, insiders, guidance and what sits behind the headline numbers. · 4 findings−29 of −35
- −12Going concern and liquidityCash of only C$63,000 and working capital of −C$11.7m at 31/7-2026; current ratio 0.03. The auditor and accounts carry a going concern qualification, and Cohort C depends on new financing.
- −10DilutionIn March 2026 C$7.1m was raised at C$0.15 (units with warrants at C$0.20–0.25 and a convertible bond at C$0.15), and C$4m of the debt was converted into shares. The merger gives Sernova shareholders only about 50% of BetaNova, before US$10m of convertible notes to insiders convert at an undisclosed price.
- −4Merger risk and governanceThe merger requires a 2/3 majority, court approval and TSX approval; there is a break fee of US$5 m, which Sernova with its empty cash can hardly bear, and insiders finance on terms that have not been disclosed.
- −3Share price trendThe stock is −41% over 52 weeks and has fallen from C$1.25 in 2021 to 0.105 – below the issue price of C$0.15 from March 2026.
Plus
Only documented strengths. · 2 findings+5 of +15
- +3Clinical validationPhase 1/2 with Cell Pouch and donor cells reached all primary and secondary endpoints; 8 of 12 patients have become insulin-independent.
- +2Insider buyingAn insider/director subscribed C$4.0m in shares at C$0.15 and a convertible bond of C$1.5m in March 2026, and insiders in both companies are behind US$10m in convertible notes in September 2026.
Caveats
What the score does not capture, or where the data is weak.
Penny analysis (Under DKK 3). Clinical biotech (Cell Pouch, an implantable 'bio-hybrid organ' for islet cells against type 1 diabetes). Fiscal year November–October; latest quarter Q3 FY2026 (to 31/7-2026) via stockanalysis – the company's own Q3 report and MD&A (PDF) could not be read. Market cap about C$39.7m (377.6m shares x C$0.105) = about DKK 184m. The company is to be merged with Seraxis into BetaNova Biotherapeutics (Seraxis is the surviving company; Sernova shareholders get about 50%, before US$10m of convertible notes are converted at an unknown price) – the analysis therefore effectively concerns a share of the merged company. Largest owners and insider trades have only been partially investigated. No analyst coverage.
Also in Pharma & medtech
The highest scores in the same industry.
